Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Fool me twice shame on me

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Jun 26, 2020 9:21am

130 Views

Post# 31194394

RE:RE:RE:RE:RE:Fool me twice shame on me

JMark80 wrote:
JMark80 wrote:

Moonshiner592 wrote: ... we should be seeing something pivital for KLY in the upcoming weeks ... if the patent is granted ...and sales for R-107 begin? ... I'm opening the champagne!

Sales for R107? WTF are you talking about?

So when does R107 go on sale? Ha!